146 related articles for article (PubMed ID: 25600502)
21. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
[TBL] [Abstract][Full Text] [Related]
22. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B
Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602
[TBL] [Abstract][Full Text] [Related]
23. A germline oncogenic MITF mutation and tumor susceptibility.
Paillerets BB; Lesueur F; Bertolotto C
Eur J Cell Biol; 2014; 93(1-2):71-5. PubMed ID: 24290354
[TBL] [Abstract][Full Text] [Related]
24. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families.
Lang J; Boxer M; MacKie RM
Br J Dermatol; 2005 Dec; 153(6):1121-5. PubMed ID: 16307646
[TBL] [Abstract][Full Text] [Related]
25. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
[TBL] [Abstract][Full Text] [Related]
26. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
27. Family-based whole-exome sequencing identifies rare variants potentially related to cutaneous melanoma predisposition in Brazilian melanoma-prone families.
Fidalgo F; Torrezan GT; Sá BCS; Barros BDF; Moredo LF; Valieris R; de Souza SJ; Duprat JP; Krepischi ACV; Carraro DM
PLoS One; 2022; 17(1):e0262419. PubMed ID: 35085295
[TBL] [Abstract][Full Text] [Related]
28. Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families.
Bartsch DK; Langer P; Habbe N; Matthäi E; Chaloupka B; Sina M; Hahn SA; Slater EP
Clin Genet; 2010 Apr; 77(4):333-41. PubMed ID: 20041885
[TBL] [Abstract][Full Text] [Related]
29. The genetics of susceptibility to cutaneous melanoma.
Newton Bishop JA; Bishop DT
Drugs Today (Barc); 2005 Mar; 41(3):193-203. PubMed ID: 15883616
[TBL] [Abstract][Full Text] [Related]
30. High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families.
Hocevar M; Avbelj M; Perić B; Zgajnar J; Besić N; Battelino T
Croat Med J; 2006 Dec; 47(6):851-4. PubMed ID: 17167857
[TBL] [Abstract][Full Text] [Related]
31. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
[TBL] [Abstract][Full Text] [Related]
32. CDKN2A mutations in multiple primary melanomas.
Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
[TBL] [Abstract][Full Text] [Related]
33. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
[TBL] [Abstract][Full Text] [Related]
34. BRAF as a melanoma susceptibility candidate gene?
Laud K; Kannengiesser C; Avril MF; Chompret A; Stoppa-Lyonnet D; Desjardins L; Eychene A; Demenais F; Lenoir GM; Bressac-de Paillerets B;
Cancer Res; 2003 Jun; 63(12):3061-5. PubMed ID: 12810628
[TBL] [Abstract][Full Text] [Related]
35. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy.
Casula M; Colombino M; Satta MP; Cossu A; Lissia A; Budroni M; Simeone E; Calemma R; Loddo C; Caracò C; Mozzillo N; Daponte A; Comella G; Canzanella S; Guida M; Castello G; Ascierto PA; Palmieri G;
Eur J Cancer; 2007 Jan; 43(1):137-43. PubMed ID: 17055252
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
[TBL] [Abstract][Full Text] [Related]
37. Role of rare germline copy number variation in melanoma-prone patients.
Fidalgo F; Rodrigues TC; Silva AG; Facure L; de Sá BC; Duprat JP; Achatz MI; Rosenberg C; Carraro DM; Krepischi AC
Future Oncol; 2016 Jun; 12(11):1345-57. PubMed ID: 27020340
[TBL] [Abstract][Full Text] [Related]
38. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
39. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.
van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584
[TBL] [Abstract][Full Text] [Related]
40. PARKIN Inactivation Links Parkinson's Disease to Melanoma.
Hu HH; Kannengiesser C; Lesage S; André J; Mourah S; Michel L; Descamps V; Basset-Seguin N; Bagot M; Bensussan A; Lebbé C; Deschamps L; Saiag P; Leccia MT; Bressac-de-Paillerets B; Tsalamlal A; Kumar R; Klebe S; Grandchamp B; Andrieu-Abadie N; Thomas L; Brice A; Dumaz N; Soufir N
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26683220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
